OncoMatch/Clinical Trials/NCT06313970
First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients
Is NCT06313970 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including QL1706 and Nab-paclitaxel for pancreatic cancer.
Treatment: QL1706 · Nab-paclitaxel · Gemcitabine · Bevacizumab — This is a multicenter, open-label, exploratory study to evaluate the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine with or without bevacizumab as first-line treatment in patients with unresectable locally advanced or metastatic pancreatic cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: immune checkpoint inhibitor
Patients who receive any prior treatments targeting the mechanism of tumor immunity, such as immune checkpoint blockades, immune checkpoint agonists, immune cell therapy, etc.
Lab requirements
Blood counts
adequate major organ function (no medication for blood component, cell growth factor correction therapy is allowed within 14 days before randomization)
Kidney function
adequate major organ function (no medication for blood component, cell growth factor correction therapy is allowed within 14 days before randomization)
Liver function
adequate major organ function (no medication for blood component, cell growth factor correction therapy is allowed within 14 days before randomization)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06313970 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages